On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions
December 5, 2024
-
REGULATORY DPP Submits Request to MOF for Scrapping Off-Year Revisions
December 5, 2024
-
REGULATORY (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
-
REGULATORY Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
-
REGULATORY Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
-
REGULATORY LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions
December 3, 2024
-
BUSINESS Lilly Japan Pitching Unique Benefits of Kisunla with AD Drug Now on Market
December 2, 2024
-
REGULATORY Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
-
REGULATORY MOF Panel Urges Annual Price Revisions on All Drugs in 2025 Budget Proposal
November 29, 2024
-
REGULATORY Japan to Require Drug Makers to Set Up Legal Post of “Stable Supply Manager”
November 29, 2024
-
REGULATORY Japan Set to Put Up 100 Billion Yen to Support Pharma under Economic Package
November 29, 2024
-
REGULATORY DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
-
COMMENTARY MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
BUSINESS Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
-
REGULATORY Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
-
REGULATORY Japan’s New Economic Package Covers Pharma-Related Steps, but Not Repeal of Off-Year Revisions
November 25, 2024
-
REGULATORY Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
-
BUSINESS Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
-
REGULATORY 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
-
BUSINESS 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…